Literature DB >> 8519662

Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.

M R Horsman1, M Nordsmark, M Høyer, J Overgaard.   

Abstract

Hydralazine can substantially decrease blood flow and increase hypoxia in transplanted tumours. Previous indirect studies have suggested that hydralazine does not induce such effects in spontaneous tumours. We have now directly investigated the ability of hydralazine to increase hypoxia in both transplanted and spontaneous murine tumours by measuring tumour oxygen partial pressure (pO2) distributions using an Eppendorf oxygen electrode. Spontaneous tumours arose at different sites in CDF1 mice, while transplanted tumours were produced by implanting a C3H mouse mammary carcinoma on the backs of the same mouse strain. Measurements of pO2 were made in anaesthetised mice immediately before and 45 min after an intravenous injection of 5 mg kg-1 hydralazine. In the transplanted tumours hydralazine significantly decreased tumour oxygenation, such that the percentage of pO2 values < or = 5 mmHg increased from 45% to 87%, and median pO2 decreased from 5 to 3 mmHg. Similar significant changes were induced by hydralazine in the spontaneous tumours, the percentage of pO2 values < or = 5 mmHg increasing from 60% to 94% while the median pO2 values decreased from 8 to 2 mmHg. These results clearly show that there is no difference in the response of transplanted and spontaneous mouse tumours to hydralazine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519662      PMCID: PMC2034065          DOI: 10.1038/bjc.1995.532

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs.

Authors:  D J Chaplin; B Acker; P L Olive
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

2.  Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo.

Authors:  J Overgaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-11       Impact factor: 7.038

3.  Tumor tissue oxygenation as evaluated by computerized-pO2-histography.

Authors:  F Kallinowski; R Zander; M Hoeckel; P Vaupel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

4.  Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors.

Authors:  J Kalmus; P Okunieff; P Vaupel
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

5.  31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia.

Authors:  E K Rofstad; P DeMuth; B M Fenton; R M Sutherland
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

6.  Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo.

Authors:  M R Horsman; K L Christensen; J Overgaard
Journal:  Int J Hyperthermia       Date:  1989 Mar-Apr       Impact factor: 3.914

7.  Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy.

Authors:  P Okunieff; F Kallinowski; P Vaupel; L J Neuringer
Journal:  J Natl Cancer Inst       Date:  1988-07-20       Impact factor: 13.506

8.  Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs.

Authors:  W D Voorhees; C F Babbs
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

9.  Enhancement of the anti-tumor effect of melphalan in experimental mice by some vaso-active agents.

Authors:  G E Adams; I J Stratford; J Godden; N Howells
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

10.  Bioreductive drugs and the selective induction of tumour hypoxia.

Authors:  J C Bremner; I J Stratford; J Bowler; G E Adams
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

View more
  4 in total

1.  Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.

Authors:  M Nordsmark; R J Maxwell; P J Wood; I J Stratford; G E Adams; J Overgaard; M R Horsman
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.

Authors:  Kate M Bailey; Heather H Cornnell; Arig Ibrahim-Hashim; Jonathan W Wojtkowiak; Charles P Hart; Xiaomeng Zhang; Rafael Leos; Gary V Martinez; Amanda F Baker; Robert J Gillies
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

3.  Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models.

Authors:  James P B O'Connor; Jessica K R Boult; Yann Jamin; Muhammad Babur; Katherine G Finegan; Kaye J Williams; Ross A Little; Alan Jackson; Geoff J M Parker; Andrew R Reynolds; John C Waterton; Simon P Robinson
Journal:  Cancer Res       Date:  2015-12-09       Impact factor: 12.701

4.  Hypoxic Stress Induced by Hydralazine Leads to a Loss of Blood-Brain Barrier Integrity and an Increase in Efflux Transporter Activity.

Authors:  Morgane Chatard; Clémentine Puech; Frederic Roche; Nathalie Perek
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.